Top

Journal of Endocrinological Investigation

Published in:

01-05-2017 | Original Article

Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial

Authors: L. Pedersen, L. L. Christensen, S. M. Pedersen, M. Andersen

Published in: Journal of Endocrinological Investigation | Issue 5/2017

Abstract

Objectives

To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate.

Design

Randomized, double-blinded, placebo-controlled study.

Setting

Odense Androgen Study—the effect of Testim and training in hypogonadal men.

Participants

Men aged 60–78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement.

Intervention

Participants were randomized to receive 5–10 g gel/50–100 mg testosterone (Testim^®, Ipsen, France) or 5–10 g gel/placebo.

Results

The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone.

Conclusion

Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.

Amory JK, Watts NB, Easley KA et al (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510. doi:10.1210/jc.2003-031110 CrossRefPubMed

Traish AM, Saad F, Feeley RJ, Guay A (2009) The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 30:477–494. doi:10.2164/jandrol.108.007245 CrossRefPubMed

Traish AM, Saad F, Guay A (2008) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23–32. doi:10.2164/jandrol.108.005751 CrossRefPubMed

Corona G, Rastrelli G, Vignozzi L et al (2012) How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 14:251–259. doi:10.1038/aja.2011.138 CrossRefPubMedPubMedCentral

Morgentaler A, Miner MM, Caliber M et al (2015) Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 90:224–251. doi:10.1016/j.mayocp.2014.10.011 CrossRefPubMed

Spitzer M, Huang G, Basaria S et al (2013) Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 9:414–424. doi:10.1038/nrendo.2013.73 CrossRefPubMed

Corrales JJ (2006) Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189:595–604. doi:10.1677/joe.1.06779 CrossRefPubMed

Malkin CJ, Pugh PJ, Jones RD et al (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89:3313–3318. doi:10.1210/jc.2003-031069 CrossRefPubMed

Frederiksen L, Glintborg D, Højlund K et al (2012) Osteoprotegerin levels decrease during testosterone therapy in aging men and are associated with changed distribution of regional fat. Horm Metab Res 45:308–313. doi:10.1055/s-0032-1323647 CrossRefPubMed

10.

Basaria S, Davda MN, Travison TG et al (2013) Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 68:153–160. doi:10.1093/gerona/gls138 CrossRefPubMed

11.

Maggio M, Snyder P, De Vita F et al (2014) Effects of transdermal testosterone treatment on inflammatory markers in elderly males. Endocr Pract 20:1170–1177. doi:10.4158/EP13357.OR CrossRefPubMedPubMedCentral

12.

Glintborg D, Christensen LL, Kvorning T et al (2013) Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men. Mediat Inflamm 2013:1–7. doi:10.1155/2013/539156 CrossRef

13.

Ehrchen JM, Sunderkotter C, Foell D et al (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86:557–566. doi:10.1189/jlb.1008647 CrossRefPubMed

14.

Sekimoto R, Kishida K, Nakatsuji H et al (2012) High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochem Biophys Res Commun 419:782–789. doi:10.1016/j.bbrc.2012.02.102 CrossRefPubMed

15.

Pedersen L, Nybo M, Poulsen M et al (2014) Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc Disord 14:196. doi:10.1186/1471-2261-14-196 CrossRefPubMedPubMedCentral

16.

Morrow DA, Wang Y, Croce K et al (2008) Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 155:49–55. doi:10.1016/j.ahj.2007.08.018 CrossRefPubMed

17.

Riancho JA (2008) Role of the Klotho gene in bone and mineral metabolism. Clin Rev Bone Miner Metab 6:31–36. doi:10.1007/s12018-008-9016-4 CrossRef

18.

Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51. doi:10.1038/36285 CrossRefPubMed

19.

Olauson H, Vervloet MG, Cozzolino M et al (2014) New insights into the FGF23-Klotho axis. Semin Nephrol 34:586–597. doi:10.1016/j.semnephrol.2014.09.005 CrossRefPubMed

20.

Xu Y, Sun Z (2015) Molecular basis of Klotho: from gene to function in aging. Endocr Rev 36:174–193. doi:10.1210/er.2013-1079 CrossRefPubMedPubMedCentral

21.

Sugiura H, Tsuchiya K, Nitta K (2011) Circulating levels of soluble α-Klotho in patients with chronic kidney disease. Clin Exp Nephrol 15:795–796. doi:10.1007/s10157-011-0511-4 CrossRefPubMed

22.

Liu H, Fergusson MM, Castilho RM et al (2007) Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317:803–806. doi:10.1126/science.1143578 CrossRefPubMed

23.

Smith RC, O’Bryan LM, Farrow EG et al (2012) Circulating αKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 122:4710–4715. doi:10.1172/JCI64986 CrossRefPubMedPubMedCentral

24.

Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM (2013) Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem 46:1079–1083. doi:10.1016/j.clinbiochem.2013.05.046 CrossRefPubMed

25.

Yamazaki Y, Imura A, Urakawa I et al (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398:513–518. doi:10.1016/j.bbrc.2010.06.110 CrossRefPubMedPubMedCentral

26.

Isakova T, Xie H, Yang W et al (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439. doi:10.1001/jama.2011.826 CrossRefPubMedPubMedCentral

27.

Ix JH, Katz R, Kestenbaum BR et al (2012) Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 60:200–207. doi:10.1016/j.jacc.2012.03.040 CrossRefPubMedPubMedCentral

28.

Semba RD, Cappola AR, Sun K et al (2011) Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci 66:794–800. doi:10.1093/gerona/glr058 CrossRefPubMed

29.

Frederiksen L, Hojlund K, Hougaard DM et al (2012) Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. Eur J Endocrinol 166:469–476. doi:10.1530/EJE-11-0565 CrossRefPubMed

30.

Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672. doi:10.1210/jcem.84.10.6079 CrossRefPubMed

31.

Vickers AJ, Altman DG (2001) Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 323:1123–1124CrossRefPubMedPubMedCentral

32.

Frost M, Wraae K, Nielsen TL et al (2013) Similar reference intervals for total testosterone in healthy young and elderly men: results from the Odense Androgen Study. Clin Endocrinol (Oxf) 78:743–751. doi:10.1111/cen.12042 CrossRef

33.

Bhasin S, Cunningham GR, Hayes FJ et al (2010) Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 95:2536–2559. doi:10.1210/jc.2009-2354 CrossRefPubMed

34.

Corona G, Giagulli VA, Maseroli E et al (2016) THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 174:R99–R116. doi:10.1530/EJE-15-0262 CrossRefPubMed

35.

Corona G, Giagulli VA, Maseroli E et al (2016) Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 39:967–981. doi:10.1007/s40618-016-0480-2 CrossRefPubMed

36.

Lue H, Kleemann R, Calandra T et al (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect Inst Pasteur 4:449–460CrossRef

37.

Leng L, Metz CN, Fang Y et al (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467–1476. doi:10.1084/jem.20030286 CrossRefPubMedPubMedCentral

38.

Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33:637–668CrossRefPubMed

39.

Hibino T, Sakaguchi M, Miyamoto S et al (2013) S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res 73:172–183. doi:10.1158/0008-5472.CAN-11-3843 CrossRefPubMed

40.

Catalán V, Gómez-Ambrosi J, Rodríguez A et al (2011) Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med Camb Mass 17:1157–1167. doi:10.2119/molmed.2011.00144 PubMedPubMedCentral

41.

McCrohon JA, Death AK, Nakhla S et al (2000) Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 101:224–226CrossRefPubMed

42.

Fejes I, Koloszár S, Závaczki Z et al (2006) Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl 52:97–102. doi:10.1080/01485010500315479 CrossRefPubMed

43.

Meng J, Ohlsson C, Laughlin GA et al (2010) Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study. Kidney Int 78:415–422. doi:10.1038/ki.2010.161 CrossRefPubMedPubMedCentral

44.

Foley RN (2009) Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol CJASN 4:1136–1139. doi:10.2215/CJN.01660309 CrossRefPubMed

45.

Sih R, Morley JE, Kaiser FE et al (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82:1661–1667. doi:10.1210/jcem.82.6.3988 CrossRefPubMed

46.

Burnett-Bowie S-AM, Mendoza N, Leder BZ (2007) Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone 40:913–918. doi:10.1016/j.bone.2006.10.016 CrossRefPubMed

47.

Stĕpán JJ, Lachman M, Zvĕrina J et al (1989) Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69:523–527. doi:10.1210/jcem-69-3-523 CrossRefPubMed

48.

Ohlsson C, Barrett-Connor E, Bhasin S et al (2011) High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 58:1674–1681. doi:10.1016/j.jacc.2011.07.019 CrossRefPubMed

49.

Shores MM, Biggs ML, Arnold AM et al (2014) Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab 99:2061–2068. doi:10.1210/jc.2013-3576 CrossRefPubMedPubMedCentral

50.

Jeppesen LL, Jorgensen HS, Nakayama H et al (1996) Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 16:749–754. doi:10.1161/01.ATV.16.6.749 CrossRefPubMed

51.

Zhu D, Hadoke PWF, Wu J et al (2016) Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci Rep 6:24807. doi:10.1038/srep24807 CrossRefPubMedPubMedCentral

52.

Muraoka K (2001) Effects of testosterone replacement on renal function and apoptosis on mesangial and renal tubule cells in rats. Yonago Acta Med 44(1):37–44

53.

Schmid C, Neidert MC, Tschopp O et al (2013) Growth hormone and Klotho. J Endocrinol 219:R37–R57. doi:10.1530/JOE-13-0285 CrossRefPubMed

Title: Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial
Authors: L. Pedersen
L. L. Christensen
S. M. Pedersen
M. Andersen
Publication date: 01-05-2017
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 5/2017
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-016-0597-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Design

Setting

Participants

Intervention

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2017

Quercetin potentiates transdifferentiation of bone marrow mesenchymal stem cells into the beta cells in vitro

Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome

A rare case of spontaneous Cushing disease remission induced by pituitary apoplexy

Geniposide accelerates proteasome degradation of Txnip to inhibit insulin secretion in pancreatic β-cells

A woman by Breu Jörg the Elder, Augsburg ca. 1515 Detroit Institute of Art

Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials